Research ArticleArticle
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation
Joachim Havla, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld and Tania Kümpfel
The Journal of Rheumatology January 2013, jrheum.120729; DOI: https://doi.org/10.3899/jrheum.120729
Joachim Havla
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Peter Lohse
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Lisa Ann Gerdes
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Reinhard Hohlfeld
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Tania Kümpfel
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation
Joachim Havla, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld, Tania Kümpfel
The Journal of Rheumatology Jan 2013, jrheum.120729; DOI: 10.3899/jrheum.120729
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation
Joachim Havla, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld, Tania Kümpfel
The Journal of Rheumatology Jan 2013, jrheum.120729; DOI: 10.3899/jrheum.120729